Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 linsitinib versus placebo in advanced adrenocortical carcinoma
2009-012820-97Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in adrenal cancer (ACC) comparing OSI-906 with Placebo (2 arms). Primary endpoint: overall survival. Started Sep 2009; status: completed.
02
Drugs
linsitinib
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2009-012820-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012820-97.